Am J Transplant, Volume 17, Suppl 3 Archives - Page 73 of 181 - ATC Abstracts

2017 American Transplant Congress
Integrative Analysis of ExomeSeq and Gene Expression Data for Identification of Novel Variants Associated with Antibody-Mediated Rejection in Kidney Transplant.
S. Pineda,^1,2 T. Sigdel,² A. Jackson,³ M. Sirota,^1,2 M. Sarwal.²
¹Institute for Computational Health Science, University of California, San Francisco (UCSF), San Francisco, CA; ²Department of Surgery, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), CA; ³Department of Medicine, Johns Hopkins, Baltimore, MD
Background: The objective of this work is to characterize the impact of the donor-recipient (D/R) HLA and non-HLA mismatches on the risk of antibody-mediated rejection…
2017 American Transplant Congress
Association of Non-HLA Antibodies with Histological Changes of Antibody Mediated Injury in Kidney Transplantation.
N. Leca,¹ I. Gimferrer,² P. Warner,² K. Nelson,² R. Bakthavatsalam,¹ L. Sibulesy,¹ B. Najafian,³ C. Robinson-Cohen,¹ B. Kestenbaum.¹
¹Division of Nephrology, University of Washington, Seattle; ²Bloodworks NW, Seattle
Solid phase assays, particularly single-antigen beads, have substantially increased the sensitivity and accuracy of antibody detection in transplantation. However, donor specific antibodies(DSA) against human leukocyte…
2017 American Transplant Congress
Impact of Antibiotic Treatment Duration for Symptomatic Lower Urinary Tract Infections in Kidney Transplant Recipients.
S. Shaikh, S. Tischer, D. Kaul, A. Naik, M. Miceli, K. Gregg, N. Leja, T. Patel.
University of Michigan, Ann Arbor, MI
Background: Urinary tract infections (UTIs) remain the most common infectious complication post kidney-transplantation and may cause significant morbidity and mortality. Treatment duration for symptomatic lower…
2017 American Transplant Congress
Strongyloides Infection in Solid Organ Transplant Recipients: A Single Center Experience and Review of the Literature.
H. El Haddad,¹ V. Hemmige,¹ A. Sofjan,² T. Lasco,³ A. Restrepo.¹
¹Dept. of Medicine, Div. of Infectious Diseases, Baylor College of Medicine, Houston, TX; ²Univ. of Houston, College of Pharmacy, Houston, TX; ³CHI Baylor St Luke's Medical Center, Houston, TX
Background: Solid Organ Transplant (SOT) recipients are at risk for Strongyloides stercoralis hyperinfection syndrome and disseminated disease. Most cases are caused by reactivation of latent…
2017 American Transplant Congress
Isoflurane Precondition Alleviated Murine Liver Ischemia and Reperfusion Injury by Restoring AMPK/mTOR-Mediated Autophagy.
Z. Rao,¹ H. Zhou,² X. Pan,¹ M. Gao,¹ Z. Wang,¹ J. Sun,¹ C. Liu,¹ Z. Ding.¹
¹Department of Anesthesiology, First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China; ²Department of Liver Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Background: Isoflurane has a pharmacological precondition effect against ischemia injury in the heart, kidney and brain, but whether and how isoflurane precondition protects livers against…
2017 American Transplant Congress
A2 Incompatible Kidney Transplantation: A Single Center Experience.
L. Kamal, M. Ajaimy, M. Lubetzky, G. DeBoccardo, P. Bedi, S. Greenstein, J. Rocca, J. Graham, M. Kinkhabwala, A. Chokechanachaisakul, A. Courson, E. Akalin.
Montefiore Medical Center Transplant Center, Albert Einstein College of Medicine, NY
Background: The new kidney allocation system implemented in December 2014 allowed for use of A2/A2B donors to B recipients. However there is no mandate by…
2017 American Transplant Congress
Eculizumab Treatment on GC3 Recurrence on Renal Graft.
G. Jeantet,¹ D. Bertrand,³ A. Lionet,² D. Anglicheau,⁴ V. Fremeaux-Bacchi,⁵ M. Le Quintrec.¹
¹Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier University Hospital, Montpellier, France; ²Department of Nephrology, Dialysis and Transplantation, Lille, France; ³Department of Nephrology, Dialysis and Renal Transplantation, Rouen, France; ⁴Transplantation Rénale, Necker Hospital, Paris, France; ⁵Immunology, Hopital Européen Georges Pompidou, Paris, France
Clinical C3G recurrence occured in more than 50% after renal transplantation and is the first cause of allograft loss at 5 years post-transplantation. Eculizumab (EC)…
2017 American Transplant Congress
Course of Donor Specific Anti-HLA Antibodies After Induction Therapy with Rituximab in Renal Transplantation.
M. Baas,¹ W. Allebes,² M. van den Hoogen,³ I. Joosten,² L. Hilbrands.¹
¹Nephrology, Radboud University Medical Center, Nijmengen, Netherlands; ²Blood Transfusion and Transplantation Immunology, Radboud University Medical Center, Nijmegen, Netherlands; ³Internal Medicine, Division of Nephrology and Kidney Transplantation, Erasmus MC, University Medical Center, Rotterdam, Netherlands
The presence of pre-existing or de novo donor-specific antibodies against HLA (DSA), is associated with a worse graft outcome after renal transplantation. B-cell depletion protocols…
2017 American Transplant Congress
The Impact of Induction Therapy on Delayed Graft Function Following Kidney Transplantation in Mated Kidneys.
T. Butler, N. Hayde.
Department of Transplantation, Albert Einstein-Montefiore, Bronx, NY
Purpose: Delayed graft function (DGF) is defined as the need for dialysis within one week of transplantation and occurs in 20-50% of deceased-donor kidney transplant…
2017 American Transplant Congress
Outcome of Liver Transplantation in Patients with Prior Bariatric Surgery.
M. Safwan,¹ M. Abouljoud,¹ R. Salgia.²
¹Divison of Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI; ²Gastroenterology, Henry Ford Hospital, Detroit, MI
Aim: To study outcomes of liver transplantation (LT) patients with prior bariatric surgery (BS).Methods: Retrospective analysis performed on patients with LT between Jan 2006 and…